Mohammed Abdulaali Sahib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammed Abdulaali Sahib has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ayad Kareem Khan
Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
1 shared publication - Haider Falih Shamikh Al-Saedi
Department of Pharmacology and Toxicology, College of Pharmacy, University of Al-Ameed, Karbala 56001, Iraq
1 shared publication - Meeqaat H. Altrufi
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Kufa, Najaf 54001, Iraq
1 shared publication - Mohammed Fanokh Al-Owaidi
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kerbala, Karbala, 56001, Iraq
1 shared publication - Mohammed Ibrahim Rasool
Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala 56001, Iraq
1 shared publication Monther Faisal Mahdi
1 shared publication
Latest Publications
- 5 November 2026
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 34
In Silico Study of the New Indole-Based ER-α Antagonists
Introduction/Objective: Globally, breast cancer remains one of the most prevalent malignancies among women. Estrogen receptor alpha (ER-α) is considered a major contributor to approximately two-thirds of breast tumors. Previous research has established the success of selective estrogen receptor modulators; however, this is challenged by acquired resistance, partial agonistic effects, and suboptimal pharmacokinetic properties. This paper was designed to explore ER-α inhibitors based on the indole scaffold. Methods: The study was conducted in terms of scaffold design and preparation, target preparation, docking, ΔG calculation, drug-likeness, dynamic simulation (MD), and Density functional theory (DFT) study. A series of indole-based motifs (1-34) were rationally designed by incorporating the indole nucleus into azetidine derivatives as a “warhead” group. Then, molecular docking using Glide-XP software against the ER-α ligand- binding domain (PDB ID: 1ERR) was performed. The docking protocol was validated by redocking the co-crystallized raloxifene. Results: Redocking of raloxifene gave an RMSD of 0.377 Å. ROC analysis using 10 known ER-α actives and 100 DUD-E decoys yielded an AUC of 0.807. Compounds 30, 31, 33, and 34 had the best docking scores, ranging from −11.50 to −11.30 kcal/mol, and formed favorable interactions within the ER-α binding site. Compounds 20, 15, 30, and 25 had the most favorable binding free energies calculated by MM-GBSA. During the 100 ns MD simulations, compounds 31 and 33 showed stable RMSD profiles and limited residue fluctuations. DFT calculations gave HOMO-LUMO energy gaps of 3.97 to 4.19 eV. SwissADME predicted generally favorable drug-like and pharmacokinetic properties. Discussion: The redocking and ROC results supported the protocol’s ability to reproduce the ligand pose and distinguish known actives from decoys. Taken together, the docking, MM-GBSA, MD, DFT, and ADME results suggest that compounds 30, 31, 33, and 34 warrant further investigation. The findings also suggest that the indole scaffold may be useful for developing compounds that target ER-α. Experimental studies are needed to confirm these predictions. Conclusion: The designed indole analogs could be promising hit compounds for the development of a new ER-α antagonist, with favorable stability, binding affinity, and drug-likeness that could be progressively optimized and produced.
- 5 November 2026
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 34
In Silico Study of the New Indole-Based ER-α Antagonists
Introduction/Objective: Globally, breast cancer remains one of the most prevalent malignancies among women. Estrogen receptor alpha (ER-α) is considered a major contributor to approximately two-thirds of breast tumors. Previous research has established the success of selective estrogen receptor modulators; however, this is challenged by acquired resistance, partial agonistic effects, and suboptimal pharmacokinetic properties. This paper was designed to explore ER-α inhibitors based on the indole scaffold. Methods: The study was conducted in terms of scaffold design and preparation, target preparation, docking, ΔG calculation, drug-likeness, dynamic simulation (MD), and Density functional theory (DFT) study. A series of indole-based motifs (1-34) were rationally designed by incorporating the indole nucleus into azetidine derivatives as a “warhead” group. Then, molecular docking using Glide-XP software against the ER-α ligand- binding domain (PDB ID: 1ERR) was performed. The docking protocol was validated by redocking the co-crystallized raloxifene. Results: Redocking of raloxifene gave an RMSD of 0.377 Å. ROC analysis using 10 known ER-α actives and 100 DUD-E decoys yielded an AUC of 0.807. Compounds 30, 31, 33, and 34 had the best docking scores, ranging from −11.50 to −11.30 kcal/mol, and formed favorable interactions within the ER-α binding site. Compounds 20, 15, 30, and 25 had the most favorable binding free energies calculated by MM-GBSA. During the 100 ns MD simulations, compounds 31 and 33 showed stable RMSD profiles and limited residue fluctuations. DFT calculations gave HOMO-LUMO energy gaps of 3.97 to 4.19 eV. SwissADME predicted generally favorable drug-like and pharmacokinetic properties. Discussion: The redocking and ROC results supported the protocol’s ability to reproduce the ligand pose and distinguish known actives from decoys. Taken together, the docking, MM-GBSA, MD, DFT, and ADME results suggest that compounds 30, 31, 33, and 34 warrant further investigation. The findings also suggest that the indole scaffold may be useful for developing compounds that target ER-α. Experimental studies are needed to confirm these predictions. Conclusion: The designed indole analogs could be promising hit compounds for the development of a new ER-α antagonist, with favorable stability, binding affinity, and drug-likeness that could be progressively optimized and produced.
- Open Access
Nicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD+ Homeostasis and Nrf2/NQO1-Dependent Antioxidant Signaling
Background: Cisplatin is a widely used chemotherapeutic agent whose clinical application is often limited by severe hepatorenal toxicity associated with oxidative stress and cellular injury. Nicotinamide riboside (NR), a natural precursor of nicotinamide adenine dinucleotide (NAD+), has emerged as a promising cytoprotective compound with antioxidant and metabolic regulatory properties. This study investigated the protective effects of NR against cisplatin-induced hepatorenal toxicity and explored its potential mechanisms of action. Methods: Thirty-six adult male Wistar rats were randomly assigned to four groups (n = 6): control, cisplatin (7 mg/kg, i.p.), nicotinamide riboside (50 mg/kg/day, orally), and cisplatin plus NR. Renal and hepatic function biomarkers, lipid profile parameters, oxidative stress markers, and antioxidant status were evaluated. Relative mRNA expression of Nrf2 and NQO1 was determined using RT-qPCR. Histopathological examinations of liver and kidney tissues were also performed. Results: Cisplatin administration induced marked hepatorenal injury, evidenced by significant elevations in serum KIM-1 (395.27 vs. 116.04 ng/mL), urea (71.16 vs. 21.33 mg/dL), creatinine (3.49 vs. 0.26 mg/dL), AST (325.83 vs. 95.16 U/L), and ALT (102.83 vs. 45.50 U/L), accompanied by dyslipidemia, oxidative stress, and severe histopathological alterations. NR treatment significantly attenuated these changes, reducing KIM-1, urea, creatinine, AST, and ALT by 55.5%, 47.8%, 48.1%, 55.4%, and 33.5%, respectively, compared with the cisplatin group. NR also improved antioxidant status by increasing GSH and SOD levels while reducing MDA and NO concentrations. Hepatic NAD+ levels and the NAD+/NADH ratio were significantly decreased by cisplatin and significantly restored by NR treatment. In addition, NR significantly upregulated the relative mRNA expression of Nrf2 and NQO1 and markedly preserved hepatic and renal histological architecture. Pharmacological inhibition of Nrf2 with ML385 significantly attenuated these protective effects of NR across biochemical, lipid, and oxidative stress parameters, confirming that they are, at least in part, Nrf2-dependent. Conclusions: Nicotinamide riboside exerts protective effects against cisplatin-induced hepatorenal toxicity that are mechanistically linked to activation of the Nrf2/NQO1 antioxidant pathway and restoration of hepatic NAD+ homeostasis. This finding supports the potential of NR as an adjunctive strategy for mitigating cisplatin-associated hepatorenal injury and warrants further preclinical and clinical investigation.
Open AccessNicotinamide Riboside Attenuates Cisplatin-Induced Hepatorenal Toxicity Through Restoration of NAD+ Homeostasis and Nrf2/NQO1-Dependent Antioxidant Signaling
Background: Cisplatin is a widely used chemotherapeutic agent whose clinical application is often limited by severe hepatorenal toxicity associated with oxidative stress and cellular injury. Nicotinamide riboside (NR), a natural precursor of nicotinamide adenine dinucleotide (NAD+), has emerged as a promising cytoprotective compound with antioxidant and metabolic regulatory properties. This study investigated the protective effects of NR against cisplatin-induced hepatorenal toxicity and explored its potential mechanisms of action. Methods: Thirty-six adult male Wistar rats were randomly assigned to four groups (n = 6): control, cisplatin (7 mg/kg, i.p.), nicotinamide riboside (50 mg/kg/day, orally), and cisplatin plus NR. Renal and hepatic function biomarkers, lipid profile parameters, oxidative stress markers, and antioxidant status were evaluated. Relative mRNA expression of Nrf2 and NQO1 was determined using RT-qPCR. Histopathological examinations of liver and kidney tissues were also performed. Results: Cisplatin administration induced marked hepatorenal injury, evidenced by significant elevations in serum KIM-1 (395.27 vs. 116.04 ng/mL), urea (71.16 vs. 21.33 mg/dL), creatinine (3.49 vs. 0.26 mg/dL), AST (325.83 vs. 95.16 U/L), and ALT (102.83 vs. 45.50 U/L), accompanied by dyslipidemia, oxidative stress, and severe histopathological alterations. NR treatment significantly attenuated these changes, reducing KIM-1, urea, creatinine, AST, and ALT by 55.5%, 47.8%, 48.1%, 55.4%, and 33.5%, respectively, compared with the cisplatin group. NR also improved antioxidant status by increasing GSH and SOD levels while reducing MDA and NO concentrations. Hepatic NAD+ levels and the NAD+/NADH ratio were significantly decreased by cisplatin and significantly restored by NR treatment. In addition, NR significantly upregulated the relative mRNA expression of Nrf2 and NQO1 and markedly preserved hepatic and renal histological architecture. Pharmacological inhibition of Nrf2 with ML385 significantly attenuated these protective effects of NR across biochemical, lipid, and oxidative stress parameters, confirming that they are, at least in part, Nrf2-dependent. Conclusions: Nicotinamide riboside exerts protective effects against cisplatin-induced hepatorenal toxicity that are mechanistically linked to activation of the Nrf2/NQO1 antioxidant pathway and restoration of hepatic NAD+ homeostasis. This finding supports the potential of NR as an adjunctive strategy for mitigating cisplatin-associated hepatorenal injury and warrants further preclinical and clinical investigation.
- Open Access
Design, In Silico, and Experimental Evaluation of Novel Naproxen–Azetidinone Hybrids as Selective COX-2 Inhibitors
The therapeutic use of non-steroidal anti-inflammatory drugs (NSAIDs) is limited by gastrointestinal and renal adverse effects caused by non-selective COX-1 and COX-2 inhibition. To address this issue, a new series of naproxen–azetidinone hybrids was rationally designed and synthesized to enhance COX-2 selectivity and reduce off-target toxicity. The synthesis involved esterification, hydrazide formation, Schiff base condensation, and intramolecular cyclization with chloroacetyl chloride. Structural characterization was achieved through FT-IR, 1H NMR, and 13C NMR analyses. In silico ADMET profiling confirmed compliance with Lipinski’s rule and predicted favorable gastrointestinal absorption. Molecular docking revealed high COX-2 binding affinities (−11.93 to −9.72 kcal/mol), while MM/GBSA analysis identified compound N4c (ΔG = −62.27 kcal/mol) as the most stable complex, surpassing meloxicam and naproxen. DFT (B3LYP/6-31G(d,p)) frontier molecular orbital analysis indicated a narrow HOMO–LUMO gap (ΔE = 2.97 eV) for N4c, suggesting high electronic reactivity and strong enzyme interaction. Molecular dynamics simulations confirmed complex stability. In vivo anti-inflammatory testing using an egg-white-induced rat paw edema model showed that N4d, N4e, and N4f achieved higher inhibition (19.22%, 16.98%, and 16.98%) than naproxen (4.3%). These results highlight 2-azetidinone–naproxen hybrids as promising selective COX-2 inhibitors with enhanced pharmacokinetic and electronic properties.
Open AccessDesign, In Silico, and Experimental Evaluation of Novel Naproxen–Azetidinone Hybrids as Selective COX-2 Inhibitors
The therapeutic use of non-steroidal anti-inflammatory drugs (NSAIDs) is limited by gastrointestinal and renal adverse effects caused by non-selective COX-1 and COX-2 inhibition. To address this issue, a new series of naproxen–azetidinone hybrids was rationally designed and synthesized to enhance COX-2 selectivity and reduce off-target toxicity. The synthesis involved esterification, hydrazide formation, Schiff base condensation, and intramolecular cyclization with chloroacetyl chloride. Structural characterization was achieved through FT-IR, 1H NMR, and 13C NMR analyses. In silico ADMET profiling confirmed compliance with Lipinski’s rule and predicted favorable gastrointestinal absorption. Molecular docking revealed high COX-2 binding affinities (−11.93 to −9.72 kcal/mol), while MM/GBSA analysis identified compound N4c (ΔG = −62.27 kcal/mol) as the most stable complex, surpassing meloxicam and naproxen. DFT (B3LYP/6-31G(d,p)) frontier molecular orbital analysis indicated a narrow HOMO–LUMO gap (ΔE = 2.97 eV) for N4c, suggesting high electronic reactivity and strong enzyme interaction. Molecular dynamics simulations confirmed complex stability. In vivo anti-inflammatory testing using an egg-white-induced rat paw edema model showed that N4d, N4e, and N4f achieved higher inhibition (19.22%, 16.98%, and 16.98%) than naproxen (4.3%). These results highlight 2-azetidinone–naproxen hybrids as promising selective COX-2 inhibitors with enhanced pharmacokinetic and electronic properties.
- Open Access
- 4 May 2025
- Published by Turkish Computational and Theoretical Chemistry in Turkish Computational and Theoretical Chemistry
- Vol. 9 (2) , 19-32
Identification of Indole Derivatives as Selective Cyclooxygenase-2 Inhibitors by Virtual Screening and Molecular Dynamic Simulation
Selective COX-2 inhibitors present a promising strategy in pain management due to their reduced adverse effects compared to non-selective COX inhibitors targeting COX-1. This study focuses on the design and virtual exploration of 8 indole derivatives using molecular docking, ADMET, and molecular dynamics (MD) simulations. Molecular docking highlighted the significance of hydrophobic and hydrophilic amino acid residues for ligand stability, with compounds 4 and 5 exhibiting notably strong in silico affinities to COX-2 (docking scores of -11.349 kcal/mol and -10.872 kcal/mol, respectively). Molecular dynamics simulations confirmed the stability of the COX-2-compound 4 complex over 50 ns, revealing consistent ligand-protein interactions through Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), and ligand binding analysis. ADMET analysis of the active compounds showed favorable drug-like profiles and desirable pharmacokinetic properties. This comprehensive computational approach sheds light on the structural dynamics and pharmacological characteristics of these indole derivatives, underscoring their potential as selective COX-2 inhibitors for pain management and paving the way for further experimental validation and clinical exploration.
- 4 May 2025
- Published by Turkish Computational and Theoretical Chemistry in Turkish Computational and Theoretical Chemistry
- Vol. 9 (2) , 19-32
Open AccessIdentification of Indole Derivatives as Selective Cyclooxygenase-2 Inhibitors by Virtual Screening and Molecular Dynamic Simulation
Selective COX-2 inhibitors present a promising strategy in pain management due to their reduced adverse effects compared to non-selective COX inhibitors targeting COX-1. This study focuses on the design and virtual exploration of 8 indole derivatives using molecular docking, ADMET, and molecular dynamics (MD) simulations. Molecular docking highlighted the significance of hydrophobic and hydrophilic amino acid residues for ligand stability, with compounds 4 and 5 exhibiting notably strong in silico affinities to COX-2 (docking scores of -11.349 kcal/mol and -10.872 kcal/mol, respectively). Molecular dynamics simulations confirmed the stability of the COX-2-compound 4 complex over 50 ns, revealing consistent ligand-protein interactions through Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), and ligand binding analysis. ADMET analysis of the active compounds showed favorable drug-like profiles and desirable pharmacokinetic properties. This comprehensive computational approach sheds light on the structural dynamics and pharmacological characteristics of these indole derivatives, underscoring their potential as selective COX-2 inhibitors for pain management and paving the way for further experimental validation and clinical exploration.
- Open Access
- 1 August 2024
- Published by An-Najah National University in Palestinian Medical and Pharmaceutical Journal
- Vol. 10 (2) , 89-100
Design, Molecular Docking, Molecular Dynamic Simulations, MM-GBSA Study, and Pharmacokinetics Prediction of New Imidazolidinone Derivatives as Selective COX-2 Inhibitors
Cyclooxygenase-2 (COX-2) is necessary for inflammation and pain, making it a prime target for anti-inflammatory drugs. Selective COX-2 inhibitors can reduce inflammation without the gastrointestinal side effects often seen with non-selective non-steroidal anti-inflammatory drugs (NSAIDs). This study aimed to find new imidazolidinone derivatives as potential selective COX-2 inhibitors. Seven imidazolidinone derivatives were designed and tested using molecular docking with Glide software; the crystal structure's source of enzyme (protein data bank code: 5KIR) and removed solvent molecules during preparation to create a clean and suitable environment for docking simulations; the binding energies of these compounds were analyzed using the Prime-MMGBSA module, molecular dynamic simulations lasting 100 nanoseconds were performed using the Desmond program, Drug-likeness properties were predicted using Swiss-ADME. Molecular docking emphasized the importance of hydrophobic and hydrophilic amino acid residues for ligand stability. Compounds 3 and 5 showed strong affinities to COX-2, with docking scores of -11.569 and -11.240 kcal/mol, respectively, compared with reference ligand rofecoxib was -9.309 kcal/mol. Molecular dynamics simulations confirmed the stability of the COX-2-compound 3 complex, revealing consistent ligand-protein interactions. MM/GBSA calculations indicated that all compounds had favorable binding free energies. Additionally, all compounds demonstrated acceptable drug-likeness profiles and desirable pharmacokinetic properties. The study identified new imidazolidinone derivatives, particularly compound 3, as potential selective COX-2 inhibitors with strong binding affinities and stable interactions. These findings support further investigation and optimization of these compounds as therapeutic agents for inflammatory conditions. The recommendation of this work will focus on the in vivo evaluation of these compounds to confirm their therapeutic potential and further refine their pharmacological profiles.
- 1 August 2024
- Published by An-Najah National University in Palestinian Medical and Pharmaceutical Journal
- Vol. 10 (2) , 89-100
Open AccessDesign, Molecular Docking, Molecular Dynamic Simulations, MM-GBSA Study, and Pharmacokinetics Prediction of New Imidazolidinone Derivatives as Selective COX-2 Inhibitors
Cyclooxygenase-2 (COX-2) is necessary for inflammation and pain, making it a prime target for anti-inflammatory drugs. Selective COX-2 inhibitors can reduce inflammation without the gastrointestinal side effects often seen with non-selective non-steroidal anti-inflammatory drugs (NSAIDs). This study aimed to find new imidazolidinone derivatives as potential selective COX-2 inhibitors. Seven imidazolidinone derivatives were designed and tested using molecular docking with Glide software; the crystal structure's source of enzyme (protein data bank code: 5KIR) and removed solvent molecules during preparation to create a clean and suitable environment for docking simulations; the binding energies of these compounds were analyzed using the Prime-MMGBSA module, molecular dynamic simulations lasting 100 nanoseconds were performed using the Desmond program, Drug-likeness properties were predicted using Swiss-ADME. Molecular docking emphasized the importance of hydrophobic and hydrophilic amino acid residues for ligand stability. Compounds 3 and 5 showed strong affinities to COX-2, with docking scores of -11.569 and -11.240 kcal/mol, respectively, compared with reference ligand rofecoxib was -9.309 kcal/mol. Molecular dynamics simulations confirmed the stability of the COX-2-compound 3 complex, revealing consistent ligand-protein interactions. MM/GBSA calculations indicated that all compounds had favorable binding free energies. Additionally, all compounds demonstrated acceptable drug-likeness profiles and desirable pharmacokinetic properties. The study identified new imidazolidinone derivatives, particularly compound 3, as potential selective COX-2 inhibitors with strong binding affinities and stable interactions. These findings support further investigation and optimization of these compounds as therapeutic agents for inflammatory conditions. The recommendation of this work will focus on the in vivo evaluation of these compounds to confirm their therapeutic potential and further refine their pharmacological profiles.